As a mage, I just want to pursue the truth

Article 80 Steel Considerations
"Abogen Biotech's business is too big, and I have limited funds. I can't invest all of it at once."

Abogen Biopharmaceuticals is a leading domestic mRNA vaccine company. They have just completed a B round of financing of up to RMB 6 million and are about to carry out a C round of investment of more than RMB 7 million.

The biomedicine field is an extremely money-consuming field, especially for companies that develop innovative drugs. It is not uncommon for billions of dollars to be wasted.

The shares strategically allocated by Cheng Gang will be unblocked in at least two years. He has a maximum of 20 million RMB in cash on hand. Even if he borrows money from Ke Chuang Bio's original shares, he can only borrow about 100 million RMB.

One hundred and twenty million yuan is invested in innovative drugs, not to mention it is wasted, you don’t even deserve to see it.

"Moreover, the possibility that Abogen can compete with foreign pharmaceutical giants in mRNA is too small," Cheng Gang reminded.

Young believes that he is in control of everything, especially after investing in Sinovation Biotech, he has a stronger voice within IDG.
"Abroad doesn't need to compete with Pfizer and Modena, it only needs to compete with Smibio. Besides, both IDG companies have invested in it."

Siwei Biopharm is another domestic biopharmaceutical company that produces mRNA.

Cheng Gang patted his forehead and said, "Science Biotechnology will be listed soon. I'm having a hard time thinking about it lately."

Young's subtext is that the mRNA vaccines of foreign pharmaceutical giants cannot enter the Chinese market at all. As long as Abbott and SVI can take over most of the Chinese market, they will be able to make a lot of money.

"You are so experienced. You have put your eggs in two baskets. You won't lose anything." Cheng Gang said with emotion: "Foreign investment banks need to be more savvy in project management."

Whether it is the success of SMIC or Abogen, IDG will get more than 10 times the return, which is equivalent to investing 2 and getting 10.
When venture capitalists invested in Internet companies, they invested in all the leading companies. As long as one of them went public, their return rate would be at least 50%.

As long as there is no failure and the company does not invest in you and is overtaken by a third party, this investment is a sure win.

Black swans can occur in any investment method, and even asset management products may collapse.

Therefore, some angel investors claim in private communications that angel investment is essentially low-risk and high-return. Of course, such talk can only be said by experts and not by laymen.

These are wild words spoken during the economic upswing. Let’s see if they still dare to say them when the economic downturn comes.

"How about it? Do you want to invest? I can give you part of IDG's shares."

This is a more advanced form of sexual intercourse, euphemistically called exchange of interests.

When someone tells you that a stock will definitely rise next week, and even tells you how many points it will rise from which day to which day, and how many shares you can buy at most, will you take action?
Cheng Gang thought for a moment and nodded, "I'll think about it and give you an answer later."

Young: “Make a decision as soon as possible. The Abogen project is very urgent and they are in urgent need of funds.”

"In fact, you don't need to set up an investment company. Isn't Kechuang Biotechnology a good ship?"

"You have already achieved complete financial freedom through this strategic placement, so why are you still struggling?"

Sharing the investment share with Cheng Gang was just a casual move for Young. His investment was more familiar and silent than what Li Miaomiao had encountered before.

Moreover, I couldn't find any violation of regulations at all, and it didn't even violate human ethics. I was just helping my friend to make connections, and my investment behavior was completely legitimate.

Cheng Gang has been around for so many years, so he must be a smart guy. He knows that Young is provoking him:

"We've seen this when we were in America. You've achieved financial freedom many years earlier than I have. Why can't you stop working all these years?" "We are the same in this respect. Anyone who has started a business cannot stop. Their excitement threshold has been raised, and daily life cannot stimulate them."

“If I don’t do something that interests me, I’ll be no different from a pile of bones in a grave. I won’t feel anything anyway.”

Cheng Gang and Young are both members of the European and American Alumni Association, and Cheng Gang is also a venture capital circle, so the two have occasionally communicated with each other.

Cheng Gang was very emotional after the meeting with Young. Although the two knew each other before, he was one level lower than Young and the communication between the two was very limited.

Cheng Gang was previously one of the investment directors of Shunwei Capital, in other words, a senior employee, while Young is a partner of IDG Capital and one of the shareholders, and a small shareholder is also a shareholder.

"If it were me before, I might not know which companies participated in Abogen's Series C investment until the Series C investment agreement was negotiated."

“Not to mention the opportunity to get investment.”

"Due to its participation in the Series A investment of Kechuang Biotech in the past two years, Shunwei Capital has also invested a lot in the biopharmaceutical field. I don't know why they didn't participate in the investment in Abogen this time."

"Although this matter is neither illegal nor against company regulations, I will still report it to Director Zheng."

"If Chairman Zheng dislikes me because of this incident and it affects my position in Sinovation Biotech, it would be a huge loss."

Cheng Gang is very self-aware. He knows that he is capable of investing in the biomedicine field. Others are willing to bring him along not because he has a PhD in biomedicine, but because he is the general manager of Ke Chuang Bio.

If he loses this job, he can only invest in a small start-up company, or become a partner in a venture capital company. His resume in scientific and technological innovation can be improved to a higher level than before.

But compared with Ke Chuang Bio, it is still far behind.

"Recently, Suzhou is building a new biopharmaceutical park. It is said that they want to vigorously develop the biopharmaceutical industry. Abogen Bio is said to be a project they strongly support."

"If Abogen can really become the next Kechuang Biopharmaceutical, then Suzhou's biopharmaceutical industry cluster can be said to be expected to be established."

A cluster cannot rely on one enterprise alone. It needs successors and other related enterprises to support the entire industrial cluster.

For example, in Hangzhou, there is not only Ali, but also a group of good Internet companies such as Ant Financial, Zhuchang, Mogujie, and Tongdun.

"Abbio is in Gusu. After Kechuang Bio goes public, we can go and do some research to see their technical strength."

"We can invest one part as Sinovation Biotech, and I can invest another part as an individual."

Cheng Gang sat in the car on the way home, thinking about all kinds of things in his mind.

"If you want to invest, you can go ahead and invest, whether it's Abogen or Swinburne, I have no objection."

"I have no objection to you setting up a venture capital company, but you must keep your public and private affairs separate and not put your personal interests above the interests of the company."

"I don't know much about the two companies you want to invest in. You decide for yourself." Cheng Gang asked Zheng Li, and Zheng Li's answer was very direct and straightforward. I have drawn the framework for you, and you cannot cross the line.

(End of this chapter)